Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
Returns on capital
Seres Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.9%
avg -282.7%
ROIC
-72.7%
avg -64.4%
ROA
4.1%
avg -44.5%
Analysis
ROE is currently the strongest return metric at 12.9% versus its period average of -282.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Thomas J. DesRosier | Executive VP, Chief Legal Officer & Secretary | USD 689.73K | 71 | — | — |
Marella Thorell | Executive VP, CFO & Treasurer | USD 667.11K | 59 | 7.50K | 0.08% |
Matthew R. Henn | President & Chief Scientific Officer | USD 492.38K | 51 | 8.00K | 0.08% |
Chris McChalicher | Executive Vice President & Chief Technology Officer | USD 142.71K | — | — | — |
Richard N. Kender | Interim CEO & Executive Chair | USD 72.5K | 70 | 50.00K | 0.52% |
Dennis Walling | Senior Vice President of Clinical Development & Head of Clinical Research | — | — | — | — |
Ann Kurowski | Senior Vice President of Regulatory Affairs | — | — | — | — |
Kelly Brady | Executive VP & COO | — | 42 | 8.68K | 0.09% |
Compensation is shown in the reported currency; data updated Sep 5, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$10,042.19
Net Transaction Value
−$10,042.19
Net selling
Most Active
Shaff Eric D.
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 17, 26Aug 17, 2026 | Shaff Eric D. Direct | Sell | $1.2K$1,196.65 |
| Aug 17, 26Aug 17, 2026 | DesRosier Thomas Direct | Sell | $373.1$373.10 |
| Aug 17, 26Aug 17, 2026 | Brady Kelly Direct | Sell | $291.2$291.20 |
| Aug 17, 26Aug 17, 2026 | Henn Matthew R Direct | Sell | $368.6$368.55 |
| May 18, 26May 18, 2026 | Henn Matthew R Direct | Sell | $579.8$579.81 |
| May 18, 26May 18, 2026 | Shaff Eric D. Direct | Sell | $2K$1,950.27 |
| May 18, 26May 18, 2026 | Brady Kelly Direct | Sell | $444.3$444.27 |
| May 18, 26May 18, 2026 | DesRosier Thomas Direct | Sell | $594.9$594.87 |
| Feb 15, 26Feb 15, 2026 | DesRosier Thomas Direct | Sell | $660.7$660.66 |
| Feb 15, 26Feb 15, 2026 | Henn Matthew R Direct | Sell | $753.8$753.83 |
1–10 of 12
Summary
Insiders reported 0 buys worth $0.00 and 12 sells worth $10,042.19 over the last 12 months. That adds up to net selling of $10,042.19. Shaff Eric D. was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -7.1% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -7.1% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Seres Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MCRB's management, answered from reported figures.
Who manages MCRB?
Seres Therapeutics, Inc. (MCRB) lists 8 active executives. The top listed executive is Dennis Walling, Senior Vice President of Clinical Development & Head of Clinical Research.
Are MCRB insiders buying or selling?
Recent insider activity shows net buying of $9.29M.
Continue the stock analysis
Jump to another research area for this company.